Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IBM Watson Health

- PMLiVE

Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

- PMLiVE

Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition

The deal includes an investigational therapy being evaluated in myelofibrosis

- PMLiVE

Novartis shares positive phase 3 results for Lutathera in neuroendocrine tumours

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia

More than 6,300 people are diagnosed with the disease every year in Europe

- PMLiVE

Novartis and Voyager enter gene therapy partnership worth over $1.2bn

The companies will advance candidates for Huntington’s disease and spinal muscular atrophy

- PMLiVE

Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH

The rare blood disease is estimated to affect only ten to 20 people per million worldwide

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

Researchers improve understanding of COVID-19 virus and future variants

The study aims to contribute to the design of future COVID-19 vaccines and drugs

- PMLiVE

Novartis’ Cosentyx receives FDA approval for hidradenitis suppurativa

The decision makes Cosentyx the first biologic treatment approved for HS in nearly a decade

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links